Sarcoidosis is a rare inflammatory condition that develops when groups of cells in your immune system form patches of swollen ...

Risk factors for increased all-cause sarcoidosis mortality included Black race, male sex, older age (>70 years of age), and Northeast residence. Mortality rates among United States veterans with ...

Sarcoidosis is a systemic disease of unknown etiology. It is characterized by the presence of non-necrotizing granulomas distributed along the lymphatics in the peribronchovascular (axial ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

nonsteroidal treatment was observed. Less than half of patients with sarcoidosis had been treated by the 1-year mark since being diagnosed with the condition, according to results published in CHEST.

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Sarcoidosis is a multi-systemic disease of unknown etiology with a clinical presentation ranging from asymptomatic disease to organ failure. While some patients with sarcoidosis have spontaneous ...

Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Considering taking supplements to treat sarcoidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of sarcoidosis. Follow the links to read common uses ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...